This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Jul;139(1):344-6.

doi: 10.1053/j.gastro.2010.05.035.

Is it time for dosing anti-TNF antibody therapy by serum level?

Caroline Kerner¹, Faten Aberra

Affiliations

PMID: 20639086
DOI: 10.1053/j.gastro.2010.05.035

Comment

Is it time for dosing anti-TNF antibody therapy by serum level?

Caroline Kerner et al. Gastroenterology. 2010 Jul.

. 2010 Jul;139(1):344-6.

doi: 10.1053/j.gastro.2010.05.035.

Authors

Caroline Kerner¹, Faten Aberra

Affiliation

¹ University of Pennsylvania, Gastroenterology Division, Philadelphia, Pennsylvania, USA.

PMID: 20639086
DOI: 10.1053/j.gastro.2010.05.035

No abstract available

PubMed Disclaimer

Comment on

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.
Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Seow CH, et al. Gut. 2010 Jan;59(1):49-54. doi: 10.1136/gut.2009.183095. Gut. 2010. PMID: 19651627

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science